🔎 Today’s Daily Sift: Longevity Instagram Version Longevity is becoming measurable. Today’s strongest signal comes from Alzheimer’s diagnostics. ALZpath signed a global licensing agreement with Abbott to help develop a blood based test for Alzheimer’s disease. That matters because brain health has been one of the hardest parts of aging to detect early, affordably, and at scale. For decades, Alzheimer’s detection often meant expensive imaging, spinal fluid testing, specialist access, or waiting until symptoms became impossible to ignore. A blood test changes the frame. Less invasive. More scalable. Potentially earlier. More accessible. At the same time, Eli Lilly’s oral GLP 1 pill is moving toward possible China approval as early as late 2026 or early 2027. That tells us where longevity is headed. Brain diagnostics. Metabolic medicine. Blood biomarkers. Earlier detection. AI assisted screening. Prevention before collapse. This is not wellness theater. This is the ...